TP53 and acute myeloid leukemia: A promising molecule ALRN-6924, which is the first ever “stapled peptide” stabilized in an alpha-helical configuration able to bind to both Murine double minute-X MDMX and MDM2, two potent inhibitors of p53, was tested in phase 1 back in 2018, however no information is currently available regarding its progress in AML [48].